Wytensin

(Guanabenz acetate)

PreclinicalSmall molecule

WWyeth-Lederle Vaccines

Wytensin is one of 6 small molecule programs targeting Bone Metastasis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Bone MetastasisActive, not recruiting

Bone MetastasisPreclinical

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Bone Metastasis

#DrugCompanyPhaseTrials

Zometa

Pfizer

Approved

12 2

Duragesic

CCephalon

Approved

—3

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

1 4

Iressa

AstraZeneca

Preclinical

1 5

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 6

Wytensin

WWyeth-Lederle Vaccines

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bone Metastasis1 trial

Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis

Terminated·KKathy Miller·N/A·NCT02443103·4 enrolled

Regulatory

FDA Approval Timeline[4]

Sep 7, 1982

WYTENSIN

NDA NDA018587

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Guanabenz acetate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Guanabenz acetate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Guanabenz acetate. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA018587). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Wyeth-Lederle Vaccines company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: WWyeth-Lederle Vaccines

Wytensin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bone Metastasis1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News